Core Insights - Absci (ABSI.US) announced a collaboration with Oracle (ORCL.US) and AMD (AMD.US) to accelerate AI-driven drug development [1] - The partnership will utilize Oracle's AI infrastructure and AMD's hardware in Absci's generative AI Drug Creation Platform [1] - The CEO of Absci emphasized that this collaboration will enhance the efficiency of delivering new therapies to patients and establish a technological foundation for next-generation AI-driven drug development processes [1] Company Developments - Absci is based in Vancouver, Washington, and focuses on biotechnology [1] - The announcement coincided with the Oracle Health and Life Sciences Summit held from September 9 to 11 in Orlando, Florida [1] - At the summit, Oracle showcased advancements in healthcare technology, including AI capabilities in its Oracle Fusion Cloud Application, aimed at streamlining supply chain operations in the healthcare industry [1]